AEF0217 / Aelis Farma - LARVOL DELTA

MDDS: Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Aelis Farma | Active, not recruiting ➔ Completed

Trial completion • Developmental Disorders • Genetic Disorders • APOE

MDDS: Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (clinicaltrials.gov) - P1/2 | N=40 | Active, not recruiting | Sponsor: Aelis Farma | Recruiting ➔ Active, not recruiting | Trial primary completion date: May 2024 ➔ Aug 2024

Enrollment closed • Trial primary completion date • Developmental Disorders • Genetic Disorders • APOE

MDDS: Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Aelis Farma | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Nov 2023 ➔ May 2024

Trial completion date • Trial primary completion date • Developmental Disorders • Genetic Disorders • APOE

MDDS: Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Aelis Farma | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: May 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Developmental Disorders • Genetic Disorders

AEF0217-101: AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects. (clinicaltrials.gov) - P1 | N=68 | Completed | Sponsor: Aelis Farma | Active, not recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ Jun 2022

Trial completion • Trial completion date

MDDS: Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Aelis Farma

New P1/2 trial • Developmental Disorders • Genetic Disorders